Zhi Tong Cai Jing·2025-11-18 10:07Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder, including this drug, is approximately RMB 6.21 million as of October 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 873 million in 2024 [1] Group 3: Regulatory Status - The drug must obtain drug registration approval and fulfill other requirements before commercial production can commence [1] - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]